Rocket Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 2.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.83M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardia...